Nuvation Bio is trading 4.05% down at $6.16 despite broader markets moving higher on August 13, 2026; no fresh company-specific announcement clearly explains the decline.
- August 6 second-quarter coverage said revenue beat estimates, but the adjusted loss was wider than expected.
- IBTROZI revenue grew 25% quarter over quarter.
- The move may reflect profit-taking or trading-specific pressure rather than a confirmed new catalyst.